Navigation Links
A study by the MUHC and McGill University opens a new door to understanding cancer
Date:8/13/2007

Montreal, 9 August 2007 - An in-depth understanding of the mechanisms that trigger cancer cell growth is vital to the development of more targeted treatments for the disease. An article published in the August 3 issue of Molecular Cell provides a key to these mechanisms that may prove crucial in the future. The paper is co-authored by Dr Morag Park, Director of the MUHC Molecular Oncology Group, and Dr Kalle Gehring, Head of the Nuclear Magnetic Resonnance Laboratory of the McGill University Biochemistry Department.

To understand cancer, it is necessary to first understand how the molecules interact, explains Dr. Park, who is also a Professor of oncology and biochemistry at McGill University. In that study we have clarified the structure of some of the proteins involved and their connections, which allows us to understand the consequences of these interactions. This is, in fact, a feat that merits close attention, because it means that researchers can now see elements smaller than a millionth of a millimetre!

In a cells interior, the function of the ubiquitin molecule is to clean house. It attaches itself to proteins that must disappear and triggers their degradation; in doing so, it allows a number of mechanisms to be minutely controlled. This new study reveals that ubiquitin also promotes interactions between proteins known as Cb-b. In a healthy patient, Cb-b is activated when a growth factor attaches itself to the surface of a cell, its role being to mitigate the cell proliferation and growth mechanisms induced by the factor. However, in some cancer patients this mitigation mechanism does not appear to function, partly because the ubiquitin does not attach itself correctly to the cell surface and to Cb-b. As a result, the effects of the growth factor become much more pronounced, which results in an unrestrained proliferation of cells that can become a cancer.

In the long term, this may serve as a basis for us to find ways to intervene in this chain reaction and discover a treatment adds Dr. Gehring. This new information about ubiquitin marks an important advance in our understanding of the mechanisms associated with cancer and contributes to the fight against the disease by directing us towards research avenues for new medications.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... JOSE, Calif. , Jan. 11, 2016 ... of human interface solutions, today announced that its ClearPad ... driver integration (TDDI) products won two separate categories in ... Best Mobile Innovator and Best Technology Breakthrough. The Synaptics ... system cost, a simplified supply chain, thinner devices, brighter ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered organ ... and bronchus, today announced that CEO Jim ... CEO & Investor Conference on Tuesday, February ... New York City . HART,s presentation ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
(Date:2/3/2016)... 2016  Silk Therapeutics, Inc., today announced the closing of ... now raised a total of $10.25 million in Series A ... Series A2 round was led by existing investor The Kraft ... from new investors Lear Corporation and Highland Consumer Partners, as ... ; Richard Sackler , MD, with Summer Road, LLC; ...
Breaking Biology Technology: